-

QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility

  • Interest rate is linked to company’s environmental, social and governance rating
  • Transaction was well received and significantly oversubscribed by eleven banks
  • QIAGEN will donate margin gains of improved ESG rating to sustainability-linked causes

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the company’s environmental, social and governance (ESG) performance.

The agreement makes QIAGEN the first provider of molecular diagnostics solutions with a sustainability component built into corporate borrowing. It underlines QIAGEN’s commitment to people and planet by creating financial incentives to further integrate sustainability throughout every part of its business.

The facility will run for three years and each lender will be able to extend this period by one year two times. It replaces a facility of the same amount that runs until December 2021 and will be used for general corporate purposes including potential acquisitions. One factor determining the new facility’s credit margin will be QIAGEN’s sustainability rating, as assigned by ISS-ESG. This independent and highly regarded sustainability-ratings agency in July 2020 awarded QIAGEN its top-flight “Prime” rating.

“Our mission to make improvements in life possible includes sustainable business practices,” said Roland Sackers, Chief Financial Officer of QIAGEN. “By linking this new credit facility to our sustainability rating, we are creating a new incentive to further foster and embed sustainability in all business areas. An improved ESG rating triggers interest-margin gains and QIAGEN will donate any money saved this way to sustainable causes.”

The syndicated credit facility is provided by a group of eleven core relationship banks and syndication was significantly oversubscribed. Deutsche Bank AG and UniCredit Bank AG were mandated as coordinators with Deutsche Bank AG acting as the Documentation and Facility Agent and UniCredit Bank AG as the sustainability coordinator.

Please find the full press release here

Contacts

John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com

Phoebe Loh
Director Investor Relations
+49 2103 29 11457 / phoebe.loh@qiagen.com

Dr. Thomas Theuringer
Senior Director, Head of External Communications
+49 2103 29 11826 / thomas.theuringer@qiagen.com

Robert Reitze
Senior Manager Public Relations
+49 2103 29 11676 / robert.reitze@qiagen.com

QIAGEN N.V.

FWB:QIA
Details
Headquarters: Venlo, Netherlands
CEO: Thierry Bernard
Employees: 5800
Organization: PUB
Revenues: US$ 1.97 billion (2023)
Net Income: US$ 341.3 million (2023)

Release Summary
QIAGEN underlines and innovates its commitment to sustainability with a EUR 400mn sustainability-linked credit facility
Release Versions
$Cashtags

Contacts

John Gilardi
Vice President Corporate Communications and Investor Relations
+49 2103 29 1171 and +49 152 018 11711 and +1 240 686 2222 / john.gilardi@qiagen.com

Phoebe Loh
Director Investor Relations
+49 2103 29 11457 / phoebe.loh@qiagen.com

Dr. Thomas Theuringer
Senior Director, Head of External Communications
+49 2103 29 11826 / thomas.theuringer@qiagen.com

Robert Reitze
Senior Manager Public Relations
+49 2103 29 11676 / robert.reitze@qiagen.com

Social Media Profiles
More News From QIAGEN N.V.

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will provide printed copies of the 2025 Annual Report to shareholders free of charge upon request. To obtain a printed copy of th...

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention glo...

QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system. With this milestone, laboratories can run both QIAstat-Dx Respiratory and QIAstat-Dx GI panels on QIAstat-Dx Rise, the high-throughput version of the QIAstat-Dx system. Both versions support compr...
Back to Newsroom